Comparative Pharmacology
Head-to-head clinical analysis: NALTREXONE HYDROCHLORIDE versus OPVEE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NALTREXONE HYDROCHLORIDE versus OPVEE.
NALTREXONE HYDROCHLORIDE vs OPVEE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at mu, kappa, and delta opioid receptors, with highest affinity for mu receptors. Also acts as an antagonist at the toll-like receptor 4 (TLR4).
Opvee is a naloxone-containing nasal spray. Naloxone is an opioid antagonist that competitively binds to mu-opioid receptors, reversing opioid-induced respiratory depression and sedation.
50 mg orally once daily for opioid dependence; 25 mg orally once daily for alcohol dependence, may increase to 50 mg after one week.
2 mg intranasally as a single dose; may repeat every 2-3 minutes if response is inadequate; maximum total dose of 4 mg.
None Documented
None Documented
Terminal elimination half-life: ~4 hours for naltrexone; its major active metabolite, 6-β-naltrexol, has a half-life of ~13 hours. The longer half-life of the metabolite contributes to sustained receptor blockade.
Terminal elimination half-life is approximately 2-4 hours (mean 2.8 hours) in healthy adults. Context: Despite short half-life, clinical antagonism of opioids can persist for 1-2 hours, potentially shorter than the opioid; repeat dosing may be needed.
Renal: primarily as unchanged drug (<2%) and metabolites (mainly 6-β-naltrexol, glucuronide conjugates); approximately 60% of dose excreted in urine (including metabolites) and about 30% in feces via biliary excretion.
Primarily renal excretion of unchanged drug (approximately 50-70%) and conjugated metabolites (glucuronide); the remainder is eliminated via biliary/fecal routes. Total renal clearance accounts for ~60% of systemic clearance.
Category A/B
Category C
Opioid Antagonist
Opioid Antagonist